[Stability of Six Drugs in Total Parenteral Nutrition Solution]. 2021

Takefumi Kumagai, and Naoko Narahara, and Eiji Sato, and Yoshitaka Kihira, and Yoshino Fujimura, and Eijiro Kojima, and Shojiro Ogawa, and Yuko Date, and Yasuto Tsuruta, and Hironori Yoshitomi, and Hirofumi Inoue
Pharmacy Co. Ltd.

Elneopa NF No. 1 and No. 2 infusions are total parenteral nutrition solutions packaged in four-chambered infusion bags. They have been used as home parenteral nutrition, with various drugs injected into the infusion bags, for treating patient symptoms. In this study, we investigated the stability of six drugs, including famotidine, scopolamine butylbromide, furosemide, bromhexine hydrochloride, betamethasone sodium phosphate, and metoclopramide hydrochloride in the infusion bags under dark conditions at 4℃ for 7 days. Additionally, we developed a high-performance liquid chromatography method to determine drug concentrations in the infusions. The concentrations of injected famotidine, scopolamine butylbromide, and betamethasone sodium phosphate remained unchanged when the four chambers of Elneopa NF No. 1 and No. 2 were opened and the infusions were mixed. Their respective concentrations in the upper and lower chambers also remained unchanged. The concentration of furosemide in the upper chamber of the No. 1 infusion bag decreased after 5 days, although no change was observed in the other chambers and the mixed infusions with the four chambers opened. The concentration of bromhexine hydrochloride slightly decreased in the upper chambers (approximately 3%) after the co-infusion but decreased significantly in the other chambers and the mixed infusions with the four chambers opened. The concentration of metoclopramide hydrochloride significantly decreased in the upper chambers after the co-infusion; however, no change in concentration was observed in the other chambers and the mixed infusion with the four chambers opened. The results of this study provide useful information on home-based parenteral nutrition.

UI MeSH Term Description Entries
D008787 Metoclopramide A dopamine D2 antagonist that is used as an antiemetic. 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide,Cerucal,Maxolon,Metaclopramide,Metoclopramide Dihydrochloride,Metoclopramide Hydrochloride,Metoclopramide Monohydrochloride,Metoclopramide Monohydrochloride, Monohydrate,Primperan,Reglan,Rimetin,Dihydrochloride, Metoclopramide,Hydrochloride, Metoclopramide,Monohydrochloride, Metoclopramide
D001964 Bromhexine A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744) Aparsonin,Bisolvon,Bromhexin,Bromhexin BC,Bromhexin Berlin-Chemie,Bromhexin-ratiopharm,Bromhexine Hydrochloride,Bromhexine Monohydrochloride,Brotussol,Darolan,Dur-Elix,Famel Bromhexine,Flegamin,Flubron,Hustentabs-ratiopharm,Mucohexine,NA-274,Quentan,Tesacof,bromhexin von ct,BC, Bromhexin,Bromhexin Berlin Chemie,Bromhexin BerlinChemie,Bromhexin ratiopharm,Bromhexine, Famel,Bromhexinratiopharm,Dur Elix,DurElix,Hustentabs ratiopharm,Hustentabsratiopharm,Hydrochloride, Bromhexine,Monohydrochloride, Bromhexine,NA 274,NA274,ct, bromhexin von,von ct, bromhexin
D002086 Butylscopolammonium Bromide Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract. Hyoscinbutylbromide,Scopolaminebutylbromide,Buscapine,Buscolysin,Buscopan,Butylscopolamine,Hyoscine N-Butylbromide,N-Butylscopolammonium Bromide,Scopolan,Bromide, Butylscopolammonium,Bromide, N-Butylscopolammonium,Hyoscine N Butylbromide,N Butylscopolammonium Bromide,N-Butylbromide, Hyoscine
D004349 Drug Packaging Containers, packaging, and packaging materials for drugs and BIOLOGICAL PRODUCTS. These include those in ampule, capsule, tablet, solution or other forms. Packaging includes immediate-containers, secondary-containers, and cartons. In the United States, such packaging is controlled under the Federal Food, Drug, and Cosmetic Act which also stipulates requirements for tamper-resistance and child-resistance. Similar laws govern use elsewhere. (From Code of Federal Regulations, 21 CFR 1 Section 210, 1993) DRUG LABELING is also available. Drug Containers and Closures,Packaging, Drug,Drug Containers,Container, Drug,Containers, Drug,Drug Container,Drug Packagings,Packagings, Drug
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D001623 Betamethasone A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724) Betadexamethasone,Flubenisolone,Celeston,Celestona,Celestone,Cellestoderm
D015738 Famotidine A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. Famotidine Hydrochloride,MK-208,Pepcid,YM-11170,MK 208,MK208,YM 11170,YM11170
D016562 Parenteral Nutrition, Home Total The at-home administering of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously or by some other non-alimentary route. Home Total Parenteral Nutrition,Nutrition, Home Total Parenteral,Total Parenteral Nutrition, Home,Home Parenteral Nutrition, Total
D057947 Parenteral Nutrition Solutions Specialized solutions for PARENTERAL NUTRITION. They may contain a variety of MICRONUTRIENTS; VITAMINS; AMINO ACIDS; CARBOHYDRATES; LIPIDS; and SALTS. Intravenous Feeding Solutions,Feeding Solutions, Intravenous,Solutions, Intravenous Feeding

Related Publications

Takefumi Kumagai, and Naoko Narahara, and Eiji Sato, and Yoshitaka Kihira, and Yoshino Fujimura, and Eijiro Kojima, and Shojiro Ogawa, and Yuko Date, and Yasuto Tsuruta, and Hironori Yoshitomi, and Hirofumi Inoue
December 1990, Pharmaceutisch weekblad. Scientific edition,
Takefumi Kumagai, and Naoko Narahara, and Eiji Sato, and Yoshitaka Kihira, and Yoshino Fujimura, and Eijiro Kojima, and Shojiro Ogawa, and Yuko Date, and Yasuto Tsuruta, and Hironori Yoshitomi, and Hirofumi Inoue
January 1995, Acta poloniae pharmaceutica,
Takefumi Kumagai, and Naoko Narahara, and Eiji Sato, and Yoshitaka Kihira, and Yoshino Fujimura, and Eijiro Kojima, and Shojiro Ogawa, and Yuko Date, and Yasuto Tsuruta, and Hironori Yoshitomi, and Hirofumi Inoue
January 1990, JPEN. Journal of parenteral and enteral nutrition,
Takefumi Kumagai, and Naoko Narahara, and Eiji Sato, and Yoshitaka Kihira, and Yoshino Fujimura, and Eijiro Kojima, and Shojiro Ogawa, and Yuko Date, and Yasuto Tsuruta, and Hironori Yoshitomi, and Hirofumi Inoue
January 1989, JPEN. Journal of parenteral and enteral nutrition,
Takefumi Kumagai, and Naoko Narahara, and Eiji Sato, and Yoshitaka Kihira, and Yoshino Fujimura, and Eijiro Kojima, and Shojiro Ogawa, and Yuko Date, and Yasuto Tsuruta, and Hironori Yoshitomi, and Hirofumi Inoue
January 2020, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Takefumi Kumagai, and Naoko Narahara, and Eiji Sato, and Yoshitaka Kihira, and Yoshino Fujimura, and Eijiro Kojima, and Shojiro Ogawa, and Yuko Date, and Yasuto Tsuruta, and Hironori Yoshitomi, and Hirofumi Inoue
July 1987, American journal of hospital pharmacy,
Takefumi Kumagai, and Naoko Narahara, and Eiji Sato, and Yoshitaka Kihira, and Yoshino Fujimura, and Eijiro Kojima, and Shojiro Ogawa, and Yuko Date, and Yasuto Tsuruta, and Hironori Yoshitomi, and Hirofumi Inoue
May 2001, Nihon rinsho. Japanese journal of clinical medicine,
Takefumi Kumagai, and Naoko Narahara, and Eiji Sato, and Yoshitaka Kihira, and Yoshino Fujimura, and Eijiro Kojima, and Shojiro Ogawa, and Yuko Date, and Yasuto Tsuruta, and Hironori Yoshitomi, and Hirofumi Inoue
September 1976, Pediatrics,
Takefumi Kumagai, and Naoko Narahara, and Eiji Sato, and Yoshitaka Kihira, and Yoshino Fujimura, and Eijiro Kojima, and Shojiro Ogawa, and Yuko Date, and Yasuto Tsuruta, and Hironori Yoshitomi, and Hirofumi Inoue
January 1985, Pediatric infectious disease,
Takefumi Kumagai, and Naoko Narahara, and Eiji Sato, and Yoshitaka Kihira, and Yoshino Fujimura, and Eijiro Kojima, and Shojiro Ogawa, and Yuko Date, and Yasuto Tsuruta, and Hironori Yoshitomi, and Hirofumi Inoue
September 1983, Journal of clinical and hospital pharmacy,
Copied contents to your clipboard!